InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.051 -0.344 (-87.09%)+
Release
13 Mar 2026 8:57AM
Price at Release
$0.395
Full Release
download
Summary
On March 13, 2026, ASX Compliance announced the immediate lifting of the suspension of trading in the securities of Immutep Limited following the company's announcement about the interim futility analysis of their TACTI-004 (KEYNOTE-F91) Phase III trial. This trial is evaluating eftilagimod alfa, Immutep's leading candidate, marking a significant development for the company.
Key Points
  • Suspension of trading in Immutep Limited securities will be lifted.
  • The reinstatement follows an announcement regarding TACTI-004 (KEYNOTE-F91) Phase III trial.
  • The trial evaluates eftilagimod alfa, Immutep's lead candidate.
  • ASX Compliance issued the announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.